Mylan Pharmaceuticals Inc v. AstraZeneca Ab

Steven W. Parmelee

Mylan challenges AstraZeneca's saxagliptin patent, citing Ashworth & Villhauer to argue 36 diabetes drug claims are obvious via lead optimization.

Judge	Cases	Inst. Rate	FWD Inv. Rate
Christopher G Paulraj	400+	58%	66%
Michael P Tierney	300+	71%	78%
Rama G Elluru	400+	62%	84%
Rama G Elluru	400+	62%	84%
Roberta Pollock	400+	70%	69%

Name	Ratings
Mylan Pharmaceuticals Inc	L5 A
Amneal Pharmaceuticals LLC	L5 A
Teva Pharmaceuticals USA Inc	L3 A
Sun Pharmaceutical Industries Ltd	L2 B
Wockhardt Bio AG	L2 B
Sun Pharma Global FZE	L2 B
Aurobindo Pharma USA Inc	L1 C

Name	Ratings
Winston & Strawn LLP	L5 B
Andrew R. Sommer	L5 E
Samuel S. Park	L2 A
Wilson Sonsini Goodrich & Rosati	L5 E
Steven W. Parmelee	L1 C
Douglas H. Carsten	L1 C
Richard Torczon	-- -- --
Jad A. Mills	-- -- --
Schiff Hardin LLP	L3 A
Sailesh K. Patel	L2 C
George C. Yu	L1 C
Duane Morris LLP	L3 E
Patrick C. Gallagher	-- -- --
Carlson Caspers Vandenburgh Lindquist Schuman PA	L1 D
Gary J. Speier	L2 B
Iain A. McIntyre	L1 B

Name	Ratings
Finnegan Henderson Farabow Garrett & Dunner LLP	L5 E
Charles E. Lipsey	-- -- --
Anthony A. Hartmann	-- -- --
David Weingarten	-- -- --
John D. Livingstone	-- -- --
McCarter & English LLP	L5 E
Eric E. Grondahl	-- -- --